ReviewInfectious diseases of poverty2016
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective.
Review in Infectious diseases of poverty, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Leishmaniasis in deployed military populations: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.Infectious diseases of poverty · 2018Pooled it
- Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Hydroxyalkyne-Bithiophene Derivatives: Synthesis and Antileishmanial Activity.Chemical biology & drug design · 2025Article
- Prunus amygdalus var. amara seed extract enhances the antileishmanial activity of miltefosine.BMC complementary medicine and therapies · 2025Article
- AI-driven analysis by identifying risk factors of VL relapse in HIV co-infected patients.Scientific reports · 2025Article
- The Lifecycle of Phlebotomus argentipes (Diptera: Psychodidae) Sand Fly in a Newly Developed Colony in Bangladesh.The American journal of tropical medicine and hygiene · 2025Article
- Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.PLoS neglected tropical diseases · 2025Article
- Leishmaniases: Strategies in treatment development.Parasite (Paris, France) · 2025Review
- Salivary antigens rPagSP02 and rPagSP06 are a reliable composite biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Scientific reports · 2024Article
- Barriers and facilitators of visceral leishmaniasis case management in the Amhara Region, Northwest Ethiopia: an exploratory qualitative study.BMC public health · 2024Article
- rPagSP02+rPagSP06 recombinant salivary antigen is a reliable biomarker for evaluating exposure to Phlebotomus argentipes in Sri Lanka.Research square · 2024Article
- Article
- Non-compaction cardiomyopathy and visceral leishmaniasis: uncommon combination with therapeutic challenges in a resource limited-setting.Sudanese journal of paediatrics · 2024Article
- Naphthoquinone fused diazepines targeting hyperamylasemia: potential therapeutic agents for diabetes and cancer.Future medicinal chemistry · 2024Article
- Micro and nanotechnologies: The little formulations that could.Bioengineering & translational medicine · 2023Review
- InhibitingPharmaceuticals (Basel, Switzerland) · 2023Article
- Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected withAntibiotics (Basel, Switzerland) · 2023Article
- Immunogenicity and protective efficacy of tuzin protein as a vaccine candidate inFrontiers in immunology · 2023Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality and major disability in the Indian subcontinent. It is most neglected tropical disease, particularly in terms of new drug development for the lack of financial returns. An elimination campaign has been running in India since 2005 that aim to reduce the incidence of VL to below 1 per 10,000 people at sub-district level. One of the major components in this endeavor is reducing transmission through early case detection followed by complete treatment. Substantial progress has been made during the recent years in the area of VL treatment, and the VL elimination initiatives have already saved many lives by deploying them effectively in the endemic areas. However, many challenges remain to be overcome including availability of drugs, cost of treatment (drugs and hospitalization), efficacy, adverse effects, and growing parasite resistance. Therefore, better emphasis on implementation research is urgently needed to determine how best to deliver existing interventions with available anti-leishmanial drugs. It is essential that the new treatment options become truly accessible, not simply available in endemic areas so that they may promote healing and save lives. In this review, we highlight the recent advancement and challenges in current treatment options for VL in disease endemic area, and discuss the possible strategies to improve the therapeutic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.